The Lancet PT-141 and Melanotan Research: Melanocortin Peptides for Sexual Dysfunction and Beyond

Lancet Insights | 2026-07-02 | 10 min read

Analysis of PT-141 (Bremelanotide) and Melanotan II melanocortin peptides, covering MC4R agonism, sexual desire mechanisms, erectile function, and research applications.

Melanocortin Peptides: PT-141 and Sexual Function Research

The Lancet has covered research on sexual dysfunction extensively, including novel peptide-based approaches. PT-141 (bremelanotide) represents a significant advancement in treating hypoactive sexual desire disorder (HSDD) through central melanocortin pathways. This analysis examines PT-141, Melanotan II, and related melanocortin peptides for sexual dysfunction research.

Melanocortin System Overview

Melanocortin Receptors

Five melanocortin receptors (MC1R-MC5R):

| Receptor | Primary Location | Function | |----------|----------------|----------| | MC1R | Melanocytes, immune cells | Skin pigmentation, inflammation | | MC2R | Adrenal cortex | Steroidogenesis (ACTH receptor) | | MC3R | Brain, gut | Energy homeostasis | | MC4R | Brain | Sexual function, appetite | | MC5R | Exocrine glands | Exocrine function |

Endogenous Ligands

Melanocortin peptides include:

• α-MSH (alpha-melanocyte-stimulating hormone)
• β-MSH
• γ-MSH
• ACTH (adrenocorticotropic hormone)
• β-endorphin (partial antagonist)

PT-141 (Bremelanotide)

Discovery and Structure

PT-141 was developed from Melanotan II:

Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Modifications:

• Cyclic structure for stability
• Enhanced MC4R selectivity
• Reduced MC1R activity (less tanning)

Mechanism of Action

PT-141 acts through central MC4R pathways:

#### Central Nervous System Effects

• Activates MC4R in hypothalamus
• Increases dopamine release
• Enhances sexual motivation
• Works independently of genital arousal

#### Comparison to PDE5 Inhibitors

| Mechanism | PT-141 | PDE5 Inhibitors | |-----------|---------|-----------------| | Target | Central (MC4R) | Peripheral (vascular) | | Effect | Sexual desire | Erectile function | | Time to onset | 30-60 minutes | 30-60 minutes | | Duration | 8-24 hours | 4-36 hours |

Clinical Research

#### Women with HSDD

The RECONNECT trials (Phase 3):

• Significant increase in sexual desire vs placebo
• Improved satisfying sexual events
• Reduced distress about sexual dysfunction
• Effective in pre- and post-menopausal women

#### Men with Erectile Dysfunction

Research supports PT-141 for ED:

• Effective in PDE5 inhibitor non-responders
• Direct erection induction possible
• Combined with PDE5 for enhanced effect
• Safe cardiovascular profile

FDA Approval

PT-141 received FDA approval as Vyleesi:

• Indication: HSDD in premenopausal women
• Administration: Subcutaneous injection
• Dosing: As-needed, max once daily
• Well-tolerated in clinical trials

Melanotan II

Structure and History

Melanotan II is the parent compound of PT-141:

Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Note: Same core sequence as PT-141

Non-Selective Activity

Melanotan II activates multiple melanocortin receptors:

• **MC1R**: Skin tanning effect
• **MC4R**: Sexual desire and erection
• Some MC3R activity

Research Applications

Melanotan II research includes:

• Sexual dysfunction studies
• Tanning/prevention of skin cancer
• Appetite suppression (MC4R)
• Research tool for melanocortin pathways

Side Effect Profile

Melanotan II produces:

• Skin darkening (MC1R)
• Spontaneous erections (MC4R)
• Nausea (transient)
• Flushing

Research Applications

In Vitro Studies

Melanocortin research:

• MC4R binding assays
• cAMP production measurement
• Neuronal cell culture
• Receptor selectivity profiling

In Vivo Research

Animal model protocols:

• Sexual behaviour paradigms
• Flank penis erection models
• Appetite/food intake studies
• Skin pigmentation measurements

Human Studies

Clinical research protocols:

• HSDD assessment scales (FSFI, FSDS-R)
• Sexual event diaries
• Validated desire questionnaires
• Safety monitoring

Quality Standards

Purity Requirements

Melanocortin peptide research requires:

• HPLC purity ≥99.5%
• Mass spectrometry verification
• Cyclic structure confirmation
• Accurate peptide content
• Batch-specific COA documentation

Storage

Melanocortin peptide stability:

• Lyophilised: -20°C, protected from light
• Reconstituted: Refrigerate, use within days
• Avoid repeated freeze-thaw

Combination Approaches

PT-141 + PDE5 Inhibitors

Research supports combination:

• Enhanced erectile response
• Addresses both desire and function
• Synergistic mechanisms
• Potential for resistant ED

Melanotan II + Sunscreen

Skin cancer prevention research:

• Melanotan II: Induces protective tanning
• Sunscreen: Blocks UV damage
• Combined protection strategy
• Under investigation

Future Directions

Novel Formulations

Ongoing development:

• Oral PT-141 formulations
• Long-acting depot injections
• Topical preparations
• Combination products

Expanded Indications

Research exploring:

• Male HSDD
• SSRI-induced sexual dysfunction
• Diabetic neuropathy sexual dysfunction
• Combination with other therapies

ZePeptide provides research-grade PT-141, Melanotan II, and melanocortin peptides with complete analytical documentation for sexual medicine research.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.